Title Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil / cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling.

  2009cited by this paper
• Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy.

  2009cited by this paper
• VEGF G-1154A is Predictive of Severe Acute Toxicities during Chemoradiotherapy for Esophageal Squamous Cell Carcinoma in Japanese Patients

  2008cited by this paper
• Favorable Genetic Polymorphisms Predictive of Clinical Outcome of Chemoradiotherapy for Stage II/III Esophageal Squamous Cell Carcinoma in Japanese

  2007cited by this paper
• Implications of circadian clocks for the rhythmic delivery of cancer therapeutics.

  2007cited by this paper
• Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma

  2006cited by this paper
• Evaluation of combined nedaplatin and docetaxel therapy for human head and neck cancer in vivo.

  2006cited by this paper
• Radiation therapy combined with cis-diammine-glycolatoplatinum (nedaplatin) and 5-fluorouracil for Japanese stage II-IV esophageal cancer compared with cisplatin plus 5-fluorouracil regimen: a retrospective study.

  2006cited by this paper
• Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer.

  2005cited by this paper
• Circadian Variability of Pharmacokinetics of 5-Fluorouracil and CLOCK T3111C Genetic Polymorphism in Patients With Esophageal Carcinoma

  2005cited by this paper
• Circadian Rhythm in Dihydropyrimidine Dehydrogenase Activity and Reduced Glutathione Content in Peripheral Blood of Nasopharyngeal Carcinoma Patients

  2005cited by this paper
• Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus.

  2003cited by this paper
• Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus.

  2003cited by this paper
• Efficacy and toxicity of nedaplatin and 5-FU with radiation treatment for advanced esophageal carcinomas.

  2003cited by this paper
• Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus

  2003cited by this paper
• Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics

  2002cited by this paper
• Chemoradiotherapy of Locally Advanced Esophageal Cancer: Long-term Follow-up of a Prospective Randomized Trial (RTOG 85-01)

  1999cited by this paper
• Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus.

  1999cited by this paper
• Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study.

  1997cited by this paper
• Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group.

  1993cited by this paper
• Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.

  1992cited by this paper
• Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion.

  1990cited by this paper
• Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile.

  1987cited by this paper

• No citing papers are available for this paper.